Drug Profile


Alternative Names: Docetaxol; NSC 628503; RP 56976; Taxotere; XPR 6976; XRP-6976

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator sanofi-aventis
  • Developer Roche; Sanofi; University of Texas M. D. Anderson Cancer Center; West German Study Group
  • Class Antineoplastics; Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer; Endometrial cancer; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Prostate cancer
  • Registered Solid tumours
  • Discontinued Fallopian tube cancer; Pancreatic cancer; Peritoneal cancer

Most Recent Events

  • 10 Jan 2017 Roche completes a phase III trial in Breast cancer (Combination therapy, Early-stage disease) in Netherlands, Belgium, Spain, Slovenia, Germany, United Kingdom, Italy, Portugal (IV) (NCT00433589)
  • 01 Feb 2016 Medivation completes a phase I trial for Prostate cancer (Late-stage disease, Combination therapy) in USA before February 2016 (NCT01565928)
  • 07 Oct 2015 Sanofi completes the phase II DECIDE trial in Head and neck cancer in Pakistan (NCT02061631)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top